Protalix Biotherapeutics, Inc. (PLX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Protalix Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The Company's primary commercial products are Elelyso (for Gaucher disease) and Elfabrio (for Fabry disease). Operations are primarily conducted in Israel, where the Company is classified as an "essential enterprise."
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $17.9 million | $18.0 million | $43.6 million | $35.2 million |
| Net Income (Loss) | $2.4 million | $3.2 million | $(1.1) million | $(3.6) million |
| Operating Income (Loss) | $2.1 million | $4.0 million | $(0.8) million | $(3.3) million |
| EPS (Diluted) | $0.03 | $0.03 | $(0.01) | $(0.05) |
| Cash & Equivalents | $13.6 million (as of Sept 30, 2025) | |||
| Short-term Deposits | $15.7 million (as of Sept 30, 2025) | |||
| Total Liquidity | $29.4 million | |||
| Debt | $0 (Convertible notes repaid in Sept 2024) |
Material Changes vs. Prior Period
- Revenue Trends: Q3 2025 revenue remained flat compared to Q3 2024 ($17.9M vs $18.0M). However, YTD 2025 revenue increased 24% to $43.6M, driven by a $4.5M increase in sales to Chiesi (Elfabrio) and a $4.0M increase in sales to Pfizer (Elelyso), partially offset by a slight decrease in sales to Fiocruz (Brazil).
- Profitability: The Company returned to profitability in Q3 2025 with a net income of $2.4M, compared to $3.2M in Q3 2024. On a YTD basis, the net loss narrowed significantly to $1.1M from $3.6M in the prior year.
- Expense Growth: R&D expenses increased 50% in Q3 2025 ($4.5M vs $3.0M) and 58% YTD ($13.9M vs $8.8M), primarily due to preparations for the Phase 2 clinical trial of PRX-115 (gout treatment).
- Working Capital: Accounts receivable increased significantly to $14.4M from $2.9M at year-end 2024, contributing to a net cash outflow from operating activities of $14.0M YTD 2025.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash and short-term deposits ($29.4M) are sufficient to satisfy capital needs for at least 12 months. The Company has $15.7M remaining available under its At-The-Market (ATM) Sales Agreement.
- Regulatory Developments:
- Elfabrio (Fabry): The EMA's CHMP issued a negative opinion in October 2025 regarding the 2 mg/kg every 4 weeks dosing regimen. The Company requested a re-examination in November 2025.
- PRX-115 (Gout): The FDA accepted the Investigational New Drug (IND) application for the Phase 2 trial in October 2025. The trial is expected to commence in Q4 2025.
- Risk Factors:
- Geopolitical: Operations in Israel face risks from regional military conflicts, though a ceasefire was announced in October 2025. The Company maintains operations as an "essential enterprise."
- Commercial: Revenue variability depends on bulk ordering patterns from partners (Chiesi, Pfizer, Fiocruz) rather than direct patient demand.
- Regulatory: Risks associated with the re-examination of the Elfabrio dosing opinion and the success of future clinical trials.
Investor Verification Checklist
- Verify the status of the EMA re-examination request for the Elfabrio 2 mg/kg dosing regimen.
- Monitor the initiation timeline and early data readouts for the PRX-115 Phase 2 gout trial.
- Assess the impact of the significant increase in accounts receivable ($11.8M YTD increase) on future cash collections.
- Review the utilization of the remaining $15.7M ATM facility and potential dilution from future equity raises.
- Track the stability of the ceasefire in Israel and its potential impact on manufacturing and supply chain continuity.